Sandostatin — CareFirst (Caremark)
Zollinger-Ellison syndrome
Initial criteria
- Treatment of Zollinger-Ellison syndrome
Reauthorization criteria
- Member is experiencing clinical benefit as evidenced by improvement or stabilization in clinical signs and symptoms since initiation of therapy
Approval duration
12 months